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The archaeal enzyme geranylgeranyl reductase
(GGR) catalyzes hydrogenation of carbon-carbon
double bonds to produce the saturated alkyl chains
of the organism’s unusual isoprenoid-derived cell
membrane. Enzymatic reduction of isoprenoid dou-
ble bonds is of considerable interest both to natural
products researchers and to synthetic biologists
interested in the microbial production of isoprenoid
drug or biofuel molecules. Here we present crystal
structures of GGR from Sulfolobus acidocaldarius,
including the structure of GGR bound to geranylger-
anyl pyrophosphate (GGPP). The structures are
presented alongside activity data that depict the
sequential reduction of GGPP to H6GGPP via the
intermediates H2GGPP and H4GGPP. We then modi-
fied the enzyme to generate sequence variants that
display increased rates of H6GGPP production or
are able to halt the extent of reduction at H2GGPP
and H4GGPP. Crystal structures of these variants
not only reveal the structural bases for their altered
activities; they also shed light onto the catalytic
mechanism employed.
INTRODUCTION
Isoprenoids, also called terpenes and terpenoids, form a large
and structurally diverse class of natural products that display a
multitude of biological functions. Isoprenoids are also a major
target in synthetic biology for the microbial production of bio-
fuels, medicines, and other commodity chemicals, such as the
antimalarial drug precursor artemisinic acid (Ro et al., 2006),
the taxol precursor taxadiene (Ajikumar et al., 2010), the bio-
diesel precursors farnesene and bisabolene (Peralta-Yahya
et al., 2011; Renninger and McPhee, 2008), and the carotenoid1028 Structure 22, 1028–1036, July 8, 2014 ª2014 Elsevier Ltd All riglycopene (Alper et al., 2005; Farmer and Liao, 2000), which
have all been produced in engineered microbes. All isoprenoids
are constructed from the isomeric five-carbon (C5) building
blocks isopentenyl pyrophosphate (IPP) and dimethylallyl pyro-
phosphate (DMAPP), which are generated by the mevalonate
pathway or the 1-deoxy-D-xylulose 5-phosphate pathway. IPP
and DMAPP are first condensed by prenyltransferases to
form isoprenoid intermediates of varying chain lengths: geranyl
pyrophosphate (GPP, C10), farnesyl pyrophosphate (FPP, C15),
or geranylgeranyl pyrophosphate (GGPP, C20). Dedicated
terpene synthases then convert these intermediates into mono-
terpene (C10), sesquiterpene (C15), or diterpene (C20) products
using carbocation-based structural rearrangements, which use
the double bonds of GPP, FPP, and GGPP as nucleophiles to
cyclize, adjust, and rearrange the carbon skeleton. Terpene syn-
thases are thus primarily responsible for the incredible structural
diversity of isoprenoid products.
Isoprenoids also form the major component of membrane
phospholipids in archaea. Unlike bacterial or eukaryotic mem-
branes, which are primarily composed of fatty acyl chains linked
to phosphoglycerol by ester bonds, archaeal membranes are
composed of isoprenoid-derived chains linked to phosphogly-
cerol by ether bonds. Here, two geranylgeranyl chains from
GGPP are first tethered to phosphoglycerol in the molecule
2,3-di-O-geranylgeranylglyceryl phosphate (DGGGP). Next, the
enzyme geranylgeranyl reductase (GGR) performs the remark-
able 16-electron reduction of all DGGGP double bonds to pro-
duce saturated alkyl chains using flavin adenine dinucleotide
(FAD) as a cofactor. Interestingly, prior studies have shown
that GGR from Sulfolobus acidocaldarius (SaGGR) is able to
reduce three out of the four double bonds of the nonnative sub-
strate GGPP to produce the hexahydro-product, H6GGPP (Sato
et al., 2008). Although GGR from Thermoplasma acidophilum
(TaGGR) can utilize nicotinamide adenine dinucleotide phos-
phate (NADPH) as a direct electron source (Nishimura and Egu-
chi, 2006), SaGGR cannot directly use NADPH or NADH (Sato
et al., 2008), and neither its ultimate in vivo source of electrons
nor any potential redox protein partners are currently known. In
addition, crystal structures of SaGGR and TaGGR have beenhts reserved
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Although SaGGR was cocrystallized with 1.0 mM GGPP,
the electron density was discontinuous and inconsistent with
GGPP; instead, n-nonane and pyrophosphate were modeled
(Sasaki et al., 2011).
In addition to being of considerable biological interest due to
its key role in archaeal membrane biosynthesis, GGR also holds
great promise for isoprenoid production in engineeredmicrobes,
as its isoprenoid double-bond reduction activity would allow for
greater tailoring of the final product. Here, reduction of isopre-
noid double bonds would decrease the reactivity and sensitivity
to oxidation of the target compound, in addition to altering its
physicochemical properties. Such features are especially bene-
ficial for isoprenoid-based biofuels; in fact, microbially produced
farnesene and bisabolene must first be hydrogenated to farne-
sane and bisabolane, respectively, to become practical bio-
diesel alternatives (Peralta-Yahya et al., 2011; Renninger and
McPhee, 2008). Further, in vivo enzymatic hydrogenation has
several advantages over chemical hydrogenation. First, the
capital cost of chemical hydrogenation would be eliminated by
simply using a strain that expresses a requisite hydrogenation
enzyme. In addition, in vivo hydrogenation would be valuable
in host organisms that use the mevalonate pathway in anaerobic
fermentation, where redox balance becomes a serious issue.
Here, GGR could play an important role in consuming excess
reducing equivalents and regenerating oxidized NAD(P)+. Enzy-
matic reduction of double bonds within the biosynthetic pathway
also raises the possibility of using an engineered enzyme that
could selectively reduce specific double bonds, as opposed to
chemical hydrogenation of an isolated final product that would
likely reduce all double bonds. Despite its potential, however,
the use of GGR in synthetic biology for the reduction of iso-
prenoids has remained largely unexplored and unstudied, as
GGR not only awaits further biochemical and structural charac-
terization but practical GGR enzymes must also be identified or
engineered.
Here we present the structure of SaGGR bound with GGPP,
along with activity data on GGPP reduction using an enzymatic
assay based onmass spectrometry. Using these results, we per-
formed structure-guided design of SaGGR to alter the reaction
rate and to tailor the extent of GGPP reduction. We generated
SaGGR variants that exhibit increased rates of H6GGPP pro-
duction and also identified additional SaGGR variants that are
capable of halting GGPP reduction at the dihydro-product,
H2GGPP, and at the tetrahydro-product, H4GGPP. Crystal struc-
tures of these SaGGR variants bound to GGPP reveal the struc-
tural bases for their altered activities and further illuminate the
catalytic mechanism of GGR, an enzyme of both biological inter-
est and potential utility in the microbial production of isoprenoid
compounds.
RESULTS AND DISCUSSION
Structure and Activity of Wild-Type SaGGR
Crystal structures of SaGGR were determined to high resolution
bound to phosphatidylglycerol (PG) and to GGPP (Table 1). Dur-
ing the preparation of this manuscript, the structure of SaGGR in
complex with a nonphysiological ligand was published (Sasaki
et al., 2011), which described the overall structure of SaGGRStructure 22, 1in detail. Briefly, SaGGR is a monomer composed of two func-
tional domains: an FAD-binding Rossmann-type fold domain
(residues 1–74) and a ligand-binding domain (residues 75–453)
(Figure 1). The overall structure closely resembles TaGGR (Xu
et al., 2010) with a root-mean-square deviation (rmsd) of 1.5 A˚
over 350 residues. SaGGR possesses an additional 60 amino
acids at the C terminus that TaGGR does not. This region is a he-
lical in nature and is contiguous with the ligand-binding domain;
it does not clearly form a domain distinct from the ligand-binding
domain.
Although our crystals were prepared without substrate,
additional density was observed in the active site (Figure S1A
available online). Lipid analysis later revealed this to be PG,
which, although not a GGR substrate, has a similar structure to
the native substrate DGGGP (Figure S1B), and it is likely that
the membrane lipid remained bound during purification. The
two chains of PG bind in separate cavities (Figure S1A), and
only one chain, which interacts with FAD, appears to be bound
in a catalytically relevant manner. The chains are separated by
Y215 and a loop region (residues 290–301). The phosphate in
the lipid head group forms salt bridge interactions with H55
and H297 and hydrogen bonds with Y340 and N294.
We also cocrystallized SaGGR with GGPP (Figures 1 and 2A).
Unexpectedly, electron density was resolved for three separate
molecules of GGPP (Figure S2A). Similar to PG, only one GGPP
molecule (GGPP1) appears to be bound in a catalytically compe-
tent manner. The hydrophobic chain from the second GGPP
molecule (GGPP2) is bound in a manner similar to the second
chain from PG. The third GGPPmolecule (GGPP3) binds SaGGR
alongside GGPP2 within the same cavity. Although electron
density was clear for all GGPP alkyl chains, disorder was
observed in the pyrophosphate head groups of some GGPP
binding sites. Only the model for GGPP1 includes both phos-
phate groups of the pyrophosphate moiety. The model for
GGPP2 contains a single phosphate, and GGPP3 is modeled
without any phosphates, and it is possible that GGPP became
dephosphorylated during the course of crystallization. There-
fore, a mixture of substrates with different degrees of phosphor-
ylation may be present, and only the phosphates that could be
confidently fit into the electron density were included in the
model. However, to avoid confusion, all GGPP-based ligands
will be referred to as GGPP.
The pyrophosphate moiety of GGPP1 binds SaGGR in a
completely different manner from the phosphate in PG. The
b-phosphate forms a hydrogen bond with the backbone
carbonyl of N90, whereas the phosphate of GGPP2 shows
similar binding interactions as the phosphate from PG: salt
bridges are formed between the pyrophosphate moiety and
H55, H297, and K343, and hydrogen bonds occur with Y340
and N294 (Figure 2A). In all three GGPP molecules, the alkyl
chains are bound by hydrophobic residues of the protein.
In the bound GGPP1 molecule that represents reactive GGPP
binding, the terminal double bond at the opposite end from the
pyrophosphate group, the D14 double bond, sits directly facing
the N5 position of FAD (3.1 A˚), from which it accepts a hydride
for its reduction. Interestingly, the GGPP methyl group adjacent
this double bond is located in the space formed between the
conserved residues F219 and W217 (Figure 2B). Because
all other geranylgeranyl double bonds of the native DGGGP028–1036, July 8, 2014 ª2014 Elsevier Ltd All rights reserved 1029
Table 1. X-Ray Data Collection and Refinement Statistics
SaGGR GGPP G91H I206F L377H F219L I206F/L377H
PDB ID code 4OPC 4OPD 4OPU 4OPL 4OPG 4OPI 4OPT
Resolution (A˚) 501.4
(1.421.4)
50–1.83
(1.86–1.83)
50–2.70
(2.75–2.70)
50–2.48
(2.52–2.48)
50–2.07
(2.11–2.07)
50–2.24
(2.28–2.24)
50–2.60
(2.64–2.60)
Space group C 1 2 1 P 1 P 2 1 2 1 2 1 P 2 1 2 1 2 1 P 2 1 2 1 2 1 P 2 1 2 1 2 1 P 2 1 2 1 2 1
Unit cell (A˚) a = 109.0 a = 63.1 a = 63.9 a = 65.3 a = 63.2 a = 63.8 a = 63.7
b = 65.3 b = 63.2 b = 82.0 b = 78.9 b = 81.7 b = 83.0 b = 82.2
c = 63.2 c = 65.1 c = 106.2 c = 106.0 c = 105.9 c = 106.4 c = 106.4
Unit cell () a = g = 90 a = 121.0 a = b = g = 90 a = b = g = 90 a = b = g = 90 a = b = g = 90 a = b = g = 90
b = 92.0 b = 90.0
g = 88.6
Total reflections 511,159 272,344 153,053 181,226 328,857 186,897 121,720
Unique reflections 83,434 75,985 15,943 19,915 34,256 27,895 17,900
Multiplicity 6.1 (4.5) 3.6 (2.6) 9.6 (8.3) 9.1 (5.7) 9.6 (8.0) 6.7 (5.4) 6.8 (5.5)
Completeness (%) 96.60 (82.40) 97.30 (93.4) 98.7 (87.2) 97.4 (77.1) 100.0 (99.9) 99.3 (93.5) 98.0 (81.4)
I/s(I) 33.7 (1.92) 11.1 (1.15) 17.8 (1.46) 28.5 (1.53) 27.7 (1.82) 23.0 (2.87) 15.3 (1.43)
Rsym 0.039 (0.506) 0.107 (0.547) 0.122 (0.892) 0.103 (0.644) 0.075 (0.890) 0.068 (0.547) 0.110 (0.816)
R factor 0.15 0.15 0.21 0.26 0.19 0.19 0.19
Rfree 0.18 0.19 0.25 0.29 0.21 0.23 0.22
Rmsd from ideal geometry
Bonds (A˚) 0.006 0.007 0.002 0.002 0.002 0.002 0.002
Angles () 1.1 1.064 0.723 0.564 0.612 0.716 0.575
Ramachandran plot
Favored (%) 99 98 98 98 98 98 97
Outliers (%) 0 0.2 0 0 0 0 0
Clashscorea 1.98 3.83 4.22 2.91 1.9 1.91 2.47
Statistics for the highest-resolution shell are shown in parentheses.
aChen et al. (2010).
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Enzyme Design for Isoprenoid Alkene Reductionsubstrate must also be reduced by FAD in the reaction cycle, all
double bonds would be positioned in a similar manner, with their
adjacent, branching methyl groups wedged between F219 and
W217. In this way, these two residues are involved in properly
orienting the substrate in order to present the double bond to
FADH2 for reduction.
Our activity studies of wild-type (WT) SaGGR with GGPP
reveal a six-electron reduction of GGPP to H6GGPP, via the in-
termediates H2GGPP andH4GGPP, with an optimal temperature
of approximately 50C and an optimal pH of approximately
5.5 (Figure S3). In the reaction, GGPP (m/z 449.2) is reduced
first to H2GGPP (m/z 451.2), which is observed only initially
and in low levels (Figure 3A; Figure S4). Subsequently, a more
significant buildup of H4GGPP (m/z 453.2) occurs, attaining
a maximum accumulation after approximately 3 min. This
H4GGPP intermediate is then consumed with concomitant for-
mation of the product, H6GGPP (m/z 455.2). The fully reduced
form, H8GGPP (expected m/z 457.2), was not detected (Fig-
ure S4). These findings are consistent with prior SaGGR results,
which also identified H6GGPP as the product with the greatest
degree of GGPP reduction (Sato et al., 2008). Time course exper-
iments yield amaximal apparent rate (vapp) of H6GGPP formation
of 12 ± 2 mM min1 and an apparent rate constant (kapp) for
H6GGPP of 0.40 ± 0.05 min
1 (Table 2). Another useful metric
to assess the rate of reaction is the time required to reach 50%1030 Structure 22, 1028–1036, July 8, 2014 ª2014 Elsevier Ltd All rigmaximal conversion (t50) of GGPP to H6GGPP, which was
6.3 min.
Engineered GGR Variants with Altered Activity
Using our crystal structure of GGPP-bound WT SaGGR, we de-
signed mutant enzymes with the goal of altering enzyme activity.
We then determined crystal structures for engineered variants
with improved activity or those that may provide insight into
the enzyme mechanism. One objective was to engineer SaGGR
to fully reduce the nonnative GGPP substrate, as reduction to
H8GGPP had not been observed in the WT enzyme. Because
the crystal structure depicted the site of the terminal, D14
GGPP double bond poised for reduction by FAD (Figure 2B),
and because our activity studies showed that three of the four
double bonds are reduced, we speculated that the remaining,
unreduced double bond was the double bond closest to the
pyrophosphate, the D2 double bond. This judgment was also
reached in prior SaGGR experiments with GGPP (Sato et al.,
2008). Therefore, we targeted the largely hydrophobic residues
lining the GGPP-binding channel for mutation to polar or posi-
tively charged residues, with the aim of bringing the pyrophos-
phate moiety deeper into the active site. We also mutated these
residues to those with smaller side chains in order to better
accommodate the pyrophosphate head group. Another objec-
tive was to inhibit unproductive binding of GGPP to the auxiliaryhts reserved
Figure 1. Overall Fold of SaGGR
The structure of SaGGR was solved to high resolution bound with GGPP
(magenta). SaGGR is a monomer composed of two functional domains, an
FAD (yellow)-binding Rossmann-type fold domain (residues 1–74) and a
ligand-binding domain (residues 75–453). Protein is shown as cyan ribbons
and FAD (C in yellow) and GGPP (C in magenta) are shown as sticks, with O in
red, N in blue, and P in orange.
Figure 2. Active Site of SaGGR
(A) SaGGR was cocrystallized with GGPP. Electron density was resolved for
three separate molecules of GGPP (Figure S2). Like PG, only one chain
(GGPP1) appears to be bound in a catalytically competent manner, with its D
14
double bond proximal to the N5 of FAD. The hydrophobic chain from the
second molecule (GGPP2) is bound in a similar manner as the second chain
from PG. The third molecule (GGPP3) binds SaGGR alongside GGPP2 within
the same cavity.
(B) The SaGGR active site showing the FAD isoalloxazine ring, GGPP1 D
14
double bond, and conserved residues W217 and F219.
FAD (C in yellow), GGPP (C in magenta), and protein residues (C in cyan) are
shown as sticks, with O in red, N in blue, and P in orange.
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GGPP3 (Figure 2A). Here we mutated residues pointed toward
these binding channels to bulkier hydrophobic residues in order
to sterically hinder noncatalytic GGPP binding.
Of the >30 SaGGR variants tested, none fully reduced GGPP
to H8GGPP. However, several mutants displayed interesting
activity profiles that significantly differed from WT SaGGR. Two
mutants, I206F and L377H, exhibited faster overall reduction of
GGPP to H6GGPP compared to WT SaGGR (Figure 3F). Time
course experiments gave vapp of H6GGPP for the I206F and
L377H mutants of 16 ± 4 and 28 ± 11 mM min1, respectively,
kapp of 0.53 ± 0.14 and 0.94 ± 0.36 min
1, respectively, and t50
of 5.0 and 3.7 min, respectively (Table 2). As with the wild-type
enzyme, the I206F and L377H mutants reduced GGPP first by
rapid formation and consumption of H2GGPP, followed by an
initial buildup of H4GGPP that precedes reduction to H6GGPP,
the final product (Figures 3B and 3C; Figure S4).
The I206F mutation was intended to obstruct noncatalytic
GGPP binding in the GGPP2 and GGPP3 binding sites deter-
mined in the WT crystal structure. The structure of this variant
confirms that F206 partially occludes the second cavity (Fig-
ure 4A; Figure S2B). Therefore, the catalytically inactive binding
conformations are unavailable to GGPP. Weak electron density
was observed for the GGPP1 position. However, the ligand could
not be modeled with full confidence and was not included in the
final structure (Figure S2B).
For the L377Hmutant, the WT SaGGR crystal structure shows
L377 residing on the enzyme’s surface, at the opening of the cat-
alytic GGPP binding site and directly adjacent the pyrophos-Structure 22, 1phate head group. Mutation of this residue to histidine was
intended to stabilize GGPP binding in its catalytic binding site.
Indeed, H377 of the mutant forms a salt bridge with the GGPP
pyrophosphate (Figure 4B), thereby improving substrate bind-
ing. Apart from its interaction with H377, GGPP binds to the
L377H in the same way as it binds to the WT enzyme, with the
terminal, D14 double bond directly adjacent the N5 of FAD
(Figure 4B).
Interestingly, a double I206F/L377H mutant produced
H6GGPP faster than either of the single I206F or L377H mutants
(Figure 4; Figure S4), with vapp, kapp, and t50 for H6GGPP of
29 ± 3 mM min1, 0.95 ± 0.09 min1, and 2.6 min, respectively
(Table 2). Overall, the I206F/L377H mutant was the fastest
SaGGR variant tested, generating H6GGPP approximately
2.4-fold faster than the WT enzyme. The crystal structure of
the I206F/L377H double mutant correspondingly depicts the028–1036, July 8, 2014 ª2014 Elsevier Ltd All rights reserved 1031
Pr
od
uc
ts
 (%
)
GGPP
H2GGPP
H4GGPP
H6GGPP
100
80
60
40
20
00 5 10 15 20 25 30
Time (min)
Pr
od
uc
ts
 (%
)
GGPP
H2GGPP
H4GGPP
H6GGPP
100
80
60
40
20
00 5 10 15 20 25 30
Time (min)
A B
Pr
od
uc
ts
 (%
)
GGPP
H2GGPP
H4GGPP
H6GGPP
100
80
60
40
20
00 5 10 15 20 25 30
Time (min)
Pr
od
uc
ts
 (%
)
GGPP
H2GGPP
H4GGPP
H6GGPP
100
80
60
40
20
00 5 10 15 20 25 30
Time (min)
C D
Pr
od
uc
ts
 (%
)
GGPP
H2GGPP
H4GGPP
H6GGPP
100
80
60
40
20
00 5 10 15 20 25 30
Time (min)
E
H
6G
G
PP
 (%
)
100
80
60
40
20
00 5 10 15 20 25 30
WT
G91H
I206F
F219L
L377H
I206F/L377H
Time (min)
F
WT I206F
L377H G91H
F219L
Figure 3. Distribution of WT and Mutant
SaGGR Reaction Products over Time
(A–E) Reaction products for (A) WT, (B) I206F, (C)
L377H, (D) G91H, and (E) F219L SaGGR.
(F) Time-dependent formation of H6GGPP
from GGPP for WT and mutant SaGRR. WT,
I206F, L377H, and I206F/L377H SaGGR produce
H6GGPP as the final product. However, the pri-
mary products of the G91H and F219Lmutants are
H2GGPP and H4GGPP, respectively. The apparent
rate of GGPP reduction to H6GGPP was enhanced
in I206F, L377H, and I206F/L377H mutants
compared to the WT.
Error bars represent standard deviations from the
mean.
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Enzyme Design for Isoprenoid Alkene Reductionfeatures of both I206F and L377H single mutant structures
described above combined in the same structure, with GGPP
also bound with its D14 double bond directly adjacent the N5 of
FAD. From these data, it appears that the rate-enhancing effects
of the individual mutations are additive.
On the other hand, another mutant, G91H, halts the reduction
of GGPP at H2GGPP (Figure 3D; Figure S4). After reaching
maximal H2GGPP levels after approximately 10 min, only a
very small quantity of H2GGPP is reduced further to H4GGPP
or to H6GGPP (Figures 3D and 3F). This is in contrast to the
H6GGPP-producing WT, I206F, L377H, and I206F/L377H en-
zymes discussed above, which do not accumulate appreciable
levels of H2GGPP at any point during the reaction. The G91H
mutant displays vapp, kapp, and t50 for H2GGPP of 25 ± 4 mM
min1, 0.83 ± 0.14 min1, and 3.0 min, respectively (Table 2).
Notably, the G91H t50 for H2GGPP is slightly greater than the
I206F/L377H t50 for H6GGPP, indicating that the fastest
H6GGPP producer performs three reductions of GGPP (from
GGPP to H6GGPP) faster than G91H performs one reduction
(from GGPP to H2GGPP). Interestingly, although mutation of
both G91 and L377 to histidine gives completely different
reactive outcomes, forming H2GGPP and H6GGPP products,
respectively, both residues in the WT SaGGR crystal structure
are located at a similar position on the surface of the enzyme,
at the opening of the same GGPP binding site. In fact, G91
and L377 sit directly across the opening from each other, with1032 Structure 22, 1028–1036, July 8, 2014 ª2014 Elsevier Ltd All rights reservedthe GGPP pyrophosphate group located
in the center. Our crystal structure of the
G91H variant shows that, like H377 in
the L377H mutant, H91 similarly forms a
salt bridge with the GGPP pyrophosphate
(Figure 4C). However, unlike in the L377H
structure, GGPP in the G91H structure is
bound in a different position, where the
GGPP substrate has slid farther into the
protein cavity, placing the D6 double
bond instead of the D14 double bond
directly adjacent the N5 of FAD.
Going one reduction further than the
G91H mutant, another SaGGR variant,
the F219L mutant, ceases GGPP reduc-
tion at H4GGPP without significant con-
version to H6GGPP (Figure 3E; Figure S4).Interestingly, F219 is a conserved residue that is thought to serve
a role in substrate binding as described above, where the GGPP
methyl group flanking the reduced double bond is wedged be-
tween F219 and the conserved W217 in order to correctly orient
the substrate double bond for reduction by FADH2. Mutation of
F219 to leucine was intended to provide more room in the sub-
strate-binding channel for the pyrophosphate head of GGPP
to move farther into the active site without compromising the
hydrophobic environment. The crystal structure of the F219L
mutant confirms that this is the case (Figure 4D). In experiments
with the F219L mutant, a small buildup of H2GGPP is observed
after the reaction is initiated, followed by the production
of H4GGPP, with vapp, kapp, and t50 for H4GGPP of 23 ± 5 mM
min1, 0.78 ± 0.15 min1, and 3.0 min, respectively (Table 2),
without significant reduction to H6GGPP (Figure 3F). It is
possible that the increased size of the active site cavity no longer
provides sufficient van der Waals interactions for efficient bind-
ing and further reduction of the substrate.
Using simple mutations derived from structure-guided design,
we have enhanced and expanded the catalytic repertoire of
SaGGR activity toward a nonnative substrate, GGPP. Three mu-
tants (I206F, L377H, and I206F/L377H) exhibit faster production
of H6GGPP than the WT, increasing the overall rate of product
formation by up to 2.4-fold. Two other mutants selectively arrest
the progression of GGPP reduction at different intermediate
stages, with G91H producing H2GGPP and F219L producing
Table 2. Kinetic Data for Wild-Type SaGGR and Its Engineered
Mutants
SaGGR Variant Product vapp (mM min
1) kapp (min
1) t50 (min)
WT H6GGPP 12 ± 2 0.40 ± 0.05 6.3
I206F H6GGPP 16 ± 4 0.53 ± 0.14 5.0
L377H H6GGPP 28 ± 11 0.94 ± 0.36 3.7
I206F/L377H H6GGPP 29 ± 3 0.95 ± 0.09 2.6
G91H H2GGPP 25 ± 4 0.83 ± 0.14 3.0
F219L H4GGPP 23 ± 5 0.78 ± 0.15 3.0
vapp, kapp, and t50 are the apparent rate, apparent rate constant, and time
to reach 50%maximal conversion fromGGPP, respectively, for the prod-
ucts indicated.
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Enzyme Design for Isoprenoid Alkene ReductionH4GGPP at rates comparable to H6GGPP formation in the
fastest H6GGPP-producing mutants. These mutants provide
customized degrees of hydrogenation for the key isoprenoid
intermediate GGPP. Overall, these results highlight the power
of structure-guided design in tailoring the kinetic and reactive
outcomes of enzymes through small changes in the protein
sequence.
Mechanistic Implications
Our structures of engineered SaGGR variants not only reveal
the structural bases for their altered reactivities, they also help
illuminate the enzymatic mechanism employed. As these struc-
tures capture snapshots of the GGPP substrate at different
stages during the reaction, the mechanism by which GGR
reduces successive double bonds of the same substrate may
be more deeply explored.
As discussed, the GGPP-bound crystal structures of the
H6GGPP-producing enzymes (WT and L377H GGR) show the
GGPP D14 double bond directly adjacent the N5 position of
the FAD cofactor. On the other hand, the structure of the
G91H mutant, which reduces just one double bond to form
H2GGPP, shows that formation of the salt bridge between H91
and the GGPP1 pyrophosphate now places the D
6 double
bond adjacent the N5 of FAD. These results suggest that the first
double bond to be reduced is the D6 double bond, whereas
the D14 double bond is the last double bond to be reduced.
Here, through its interaction with the GGPP1 pyrophosphate,
the G91H mutant obstructs translocation of the H2GGPP inter-
mediate to inhibit further reduction (Figure 4C). This reduction
sequence implies that the double bond between D6 and D14,
the D10 double bond, is the second to be reduced. Because
H8GGPP is not formed by any enzyme, these data suggest
that the D2 double bond is left intact, consistent with prior
studies (Sato et al., 2008). In all, our SaGGR structures indicate
that GGR first reduces GGPP at the D6 double bond, then at D10,
and finally at D14 (Figure S2C).
Interestingly, in the structure of the F219L mutant that per-
forms two reductions of GGPP to H4GGPP, GGPP1 is bound in
the same manner as in the WT and L377H structures, with the
D14 double bond adjacent the N5 of FAD (Figure 4D). This obser-
vation suggests that the F219L variant first reduces the D10 dou-
ble bond before reducing theD14 double bond, giving the GGPP1
position represented in the structure and consistent with the
order of reduction described above.Structure 22, 1Although the order of double-bond reduction is suggested
by the structures, the structures do not indicate whether GGR
employs a processive mechanism or not, that is, whether the
enzyme successively reduces the double bonds of a single
substrate molecule before moving on to the next, or whether
H2GGPP or H4GGPP intermediates dissociate from the enzyme
before the final H6GGPP product is made. However, the mass
spectrometry data indicate that the mechanism of H6GGPP for-
mation is not processive, as before H6GGPP is made, GGPP
continues to be consumed to form H2GGPP and H4GGPP,
allowing a clear buildup of the intermediate H4GGPP. Therefore,
H4GGPP must dissociate from the enzyme, enabling the next
molecule of GGPP to bind and be reduced, before reduction
of H4GGPP to H6GGPP proceeds. However, it is difficult to
determine whether the first two GGPP reductions, first to
H2GGPP and then to H4GGPP, are processive. On the one
hand, a processive mechanism to H4GGPP appears to be sup-
ported by the data, as no significant buildup of H2GGPP is
observed. However, it is also possible that the second reaction
to form H4GGPP is sufficiently faster than the first to allow rapid
reduction of H2GGPP, making the first step rate determining.
Additional studies may be performed to further explore the
processivity of GGR reduction. Although it is possible that the
native reaction with DGGGP may not follow the same mecha-
nism, this is unlikely, as the enzyme catalyzes the reduction
of the same geranylgeranyl moiety of both GGPP and DGGGP
substrates.
Conclusions
The crystal structure of WT SaGGR bound with GGPP was
determined, which unexpectedly showed three binding sites
for GGPP and revealed how the enzyme orients double bonds
to be reduced by the bound FAD cofactor. Structure-guided
design of the enzyme yielded SaGGR variants that enhanced
the rate of H6GGPP product formation. Interestingly, additional
mutants were observed to arrest the degree of GGPP reduction
at H2GGPP and H4GGPP. Crystal structures of these variants
reveal the structural bases for their altered activities, in addition
to providing insight into the SaGGR mechanism.
With these GGR variants, the degree of GGPP reduction can
be customized enzymatically, a feature that is particularly useful
in synthetic biology. As GGPP is a key intermediate in the pro-
duction of countless isoprenoid-derived products, including all
diterpenes, retinoids, and carotenoids, modified GGRs such as
thesemay be used to tailor the degree of hydrogenation and alter
the isoprenoid product profile. Because terpene synthases rely
on double bonds at specific positions to rearrange the carbon
skeleton, the use ofmodifiedGGRs to selectively reduce specific
GGPP double bonds can redirect the reactive outcome toward
different products. In addition, it is useful that, as with the WT
enzyme, no SaGGR variants reduced the D2 double bond, as a
double bond in this position is necessary for providing the reso-
nance-stabilized allylic carbocation in subsequent reactions that
involve removal of the pyrophosphate group; if the D2 double
bond were reduced, the resulting H8GGPP would be a dead-
end product. Because our engineered enzymes exhibit altered
product profiles, these studies pave the way for the use of modi-
fied GGRs in the microbial production of tailored isoprenoid
products.028–1036, July 8, 2014 ª2014 Elsevier Ltd All rights reserved 1033
Figure 4. Active Sites of Engineered SaGGR
Variants
(A) The I206F mutant shows increased activity
compared to WT SaGGR. GGPP1 and GGPP2
are not present in this structure but have been
modeled in to demonstrate that F206 partially
occludes the second cavity. Therefore, this cata-
lytically inactive binding conformation is unavai-
lable toGGPP. I206 from theWT structure (orange)
has been overlaid with F206 to demonstrate the
steric hindrance caused by the introduction of a
bulky phenylalanine.
(B) The L377H mutant shows improved activity
over WT and I206F and reduces three of the four
GGPP double bonds. H377 forms a salt bridge
with the GGPP pyrophosphate.
(C) The G91H mutant reduces only one GGPP
double bond. H91 forms a salt bridge with the
GGPP pyrophosphate, with the D6 double bond
adjacent the N5 of FAD.
(D) The F219L mutant only reduces two GGPP
double bonds. The mutation increases the size of
the active site cavity and may no longer provide
sufficient van der Waals interactions for efficient
binding and reduction of substrate.
FAD (C in yellow), GGPP (C in magenta), and
protein residues (C in cyan) are shown as sticks,
with O in red, N in blue, and P in orange.
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Plasmid Construction
A codon-optimized gene encoding SaGGR was synthesized (GenScript) with
flanking NdeI and BamHI restriction sites. The gene cassettes were digested
with NdeI and BamHI and ligated into pSKB3, a plasmid that confers kana-
mycin resistance and encodes a tobacco etch virus (TEV) protease-cleavable
N-terminal hexahistidine tag to aid in protein purification. Mutant SaGGR con-
structs were made by standard oligonucleotide-directed PCR mutagenesis
using pSKB3-SaGGR as a template and the complementary oligonucleotides
listed in Table S1 as primers. All constructs were verified by DNA sequencing
(Quintara Biosciences).
Protein Overexpression and Purification
Plasmids were transformed into Escherichia coli BLR(DE3) or Rosetta2(DE3)
pLysS cells for overexpression. Cells were grown in lysogeny broth or terrific
brothmedium supplemented with 50 mg/ml kanamycin, or 50 mg/ml kanamycin
plus 34 mg/ml chloramphenicol in the case of the Rosetta2(DE3)pLysS cells, at
37C to an OD600 of 0.5–0.7, when the cultures were transferred to 18C. Over-
night overexpression was then induced with 0.1–0.5 mM isopropyl b-D-1-thi-
ogalactopyranoside. Cells were harvested by centrifugation at 5,000 3 g for
15 min at 4C, flash-frozen in liquid nitrogen, and stored at 80C until use.
Cells were thawed and resuspended in lysis buffer (20 mM NaH2PO4
[pH 7.4], 200 mM NaCl, 20 mM imidazole), and phenylmethylsulfonyl fluoride
and Benzonase (EMD Millipore) were added at 0.5 mM and 5 U/ml concentra-
tions, respectively. Cell lysis was performed by sonication, and cell debris was
pelleted by centrifugation at 50,000 3 g for 30 min. Soluble extracts were
incubated with Ni-NTA resin for 1 hr at 4C and loaded onto a column. The
flowthrough was discarded and the resin was washed with approximately 10
column volumes of lysis buffer containing 40mM imidazole. Protein was eluted
with lysis buffer containing 250 mM imidazole, and yellow fractions represent-
ing FAD-bound GGR were collected and pooled. The purified protein was
buffer exchanged into lysis buffer by either overnight dialysis or cycles of pro-
tein concentration and dilution.
To remove the hexahistidine tag, EDTA (0.5 mM), dithiothreitol (1 mM),
and hexahistidine-tagged TEV protease (approximately 1:100 molar ratio
compared to GGR) were added. Reactions were mixed and incubated over-
night at room temperature. TEV protease, cleaved hexahistidine tags, and1034 Structure 22, 1028–1036, July 8, 2014 ª2014 Elsevier Ltd All rigany remaining uncleaved SaGGR were removed by passing the solution
through Ni-NTA resin pre-equilibrated with lysis buffer and collecting the
flowthrough. Successful cleavage of the tag and the purity of SaGGR were as-
sessed by SDS-PAGE. The protein was then buffer exchanged into 20 mM
NaH2PO4 (pH 7.4) using a Sephadex G-25 column (GE Healthcare) and
concentrated to 7–10 mg/ml. Final protein concentrations were determined
by the Bradford method (Bradford, 1976) and by the absorbance at 280 nm
using a calculated extinction coefficient, ε, of 82,100 M1 cm1. Protein sam-
ples were either used directly or aliquoted, flash-frozen in liquid nitrogen, and
stored at 80C until use.
Enzymatic Assays
Reactions were performed at least in triplicate and contained 100 mM 2-(N-
morpholino)ethanesulfonic acid (MES) (pH 5.5), 20 mM sodium dithionite,
200 mM FAD, and 100 mM GGPP. Reaction mixtures were preheated to 50C
and initiated by the addition of 30 mM purified SaGGR. The reactions were
mixed and incubated at 50C for varying durations. Reactions were quenched
and extracted with an equal volume of n-butanol. In experiments that deter-
mined the pH optimum, 100 mM citric acid/sodium citrate (pH 2.5–5.0), MES
(pH 5.5–6.5), and NaH2PH4/Na2HPO4 (pH 7.0–8.0) were used as reaction
buffers in place of MES (pH 5.5). In experiments that determined the temper-
ature optimum, reactionmixtures were preheated to varying temperatures on a
thermal cycler, and purified WT SaGGR was added to initiate the reaction.
To screen SaGGR variants for the extent of GGPP reduction, the organic
phase was analyzed by liquid chromatography-mass spectrometry (LC-MS).
Reaction products were separated by HPLC (Agilent Technologies) using a
2.1 3 150 mm ZIC-pHILIC column (EMD Millipore) and an isocratic elution of
64% (v/v) acetonitrile and 36% (v/v) 50 mM ammonium acetate in water at a
flow rate of 0.15 ml/min at 40C. The HPLC system was coupled to a triple
quadrupole mass spectrometer (Applied Biosystems). Electrospray ionization
(ESI) was conducted in the negative-ion mode, and single-ion monitoring was
used for the detection of [M-H] ions at approximately 449, 451, 453, and 455
m/z, representing GGPP, H2GGPP, H4GGPP, and H6GGPP, respectively.
To quantify GGPP and its reactions products for WT SaGGR and select mu-
tants, the organic phasewas analyzed by LC-TOF (time-of-flight) MS. Reaction
products were separated by HPLC using a ZIC-pHILIC column (Merck
SeQuant, via The Nest Group) and an isocratic elution of 62% (v/v) acetonitrile
and 37% (v/v) 50mMammonium carbonate inwater at a flow rate of 0.2ml/minhts reserved
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Enzyme Design for Isoprenoid Alkene Reductionat 40C. The HPLC system was coupled to a TOF mass spectrometer (Agilent
Technologies). ESI was conducted in the negative-ion mode, and MS experi-
ments were carried out in full-scan mode, at 0.86 spectra/s for the detection of
[M-H] ions. The instrument was tuned for a range of 50–1,700 m/z. Data
acquisition and processing were performed by the MassHunter software
package (Agilent Technologies). Analytes were quantified using seven-point
calibration curves (1.5625–100 mM GGPP) whose R2 coefficients were >0.99.
The total concentrations of all reaction products varied between samples,
perhaps due to differences in extraction efficiency. Therefore, insteadof directly
establishing absolute concentrations for each product, relative concentrations
were first determinedandas a percentage of the total products for eachsample.
Apparent reaction rates, vapp, for each sample were thus determined initially
in units of % min1, which were then converted to mM min1 given the initial
substrate concentration of 100 mM. The validity of this unit conversion rests
only on the assumption that GGPP, H2GGPP, H4GGPP, and H6GGPP extract
with approximately equal efficiencies, which we believe is reasonable.
Crystallization
Purified WT and mutant SaGGR were concentrated to 10 mg/ml in a buffer
containing 25 mM HEPES (pH 7.4). Crystallization screening was carried out
on a Phoenix robot (Art Robbins Instruments) using a sparse matrix-screening
method (Jancarik and Kim, 1991). Proteins were crystallized by sitting-drop va-
por diffusion in drops containing a 1:1 ratio of protein solution and 0.1MTris (pH
7.5), 10%PEG3350, and 0.2ML-proline. An additional 5mMGGPPwas added
to the crystallization buffer to obtain the ligand-bound crystals. Yellow crystals
were observed within 2 days. For data collection, crystals were flash-frozen in
liquid nitrogen from a solution containing mother liquor and 10% glycerol.
X-Ray Data Collection and Structure Determination
The X-ray diffraction data for SaGGRwere collected at the Berkeley Center for
Structural Biology beamlines 8.2.1 and 8.2.2 of the Advanced Light Source at
Lawrence Berkeley National Laboratory. Diffraction data were recorded using
ADSC Q315R detectors (Area Detector Systems Corporation). Processing of
image data was performed using the HKL2000 suite of programs (Otwinowski
and Minor, 1997). For the WT structure, phases were calculated by molecular
replacement with the program Phaser (McCoy et al., 2007), using the structure
of TaGGR (Protein Data Bank [PDB] ID code 3OZ2) (Xu et al., 2010) as a search
model. Automatedmodel building was conducted using AutoBuild (Terwilliger,
2003) from the PHENIX suite of programs (Adams et al., 2010), resulting in a
model that was 85% complete. Manual building using Coot (Emsley and Cow-
tan, 2004) was alternated with reciprocal space refinement using PHENIX
(Afonine et al., 2012). Waters were automatically placed using PHENIX and
manually added or deleted with Coot according to peak height (>3.0 s in the
Fo  Fc map) and the distance to a potential hydrogen-bonding partner
(<3.5 A˚). Translation/libration/screw refinement (Winn et al., 2001) of ten
groups, chosen by the TLSMD web server (Painter and Merritt, 2006), was
used in later rounds of refinement. All mutant structures were refined and built
in the same manner as the WT model. All data collection, phasing, and refine-
ment statistics are summarized in Table 1.
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